Hologic, Inc. (NASDAQ:HOLX) is Lecap Asset Management Ltd.'s 3rd Largest Position

Lecap Asset Management Ltd. lifted its stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 30.0% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 65,592 shares of the medical equipment provider's stock after acquiring an additional 15,131 shares during the period. Hologic accounts for 0.9% of Lecap Asset Management Ltd.'s portfolio, making the stock its 3rd largest position. Lecap Asset Management Ltd.'s holdings in Hologic were worth $4,052,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Principal Financial Group Inc. grew its holdings in Hologic by 0.6% in the fourth quarter. Principal Financial Group Inc. now owns 271,152 shares of the medical equipment provider's stock worth $19,547,000 after purchasing an additional 1,606 shares during the last quarter. Farther Finance Advisors LLC boosted its position in shares of Hologic by 22.3% in the 1st quarter. Farther Finance Advisors LLC now owns 1,835 shares of the medical equipment provider's stock worth $113,000 after purchasing an additional 335 shares in the last quarter. SG Americas Securities LLC grew its stake in Hologic by 116.6% during the 1st quarter. SG Americas Securities LLC now owns 9,609 shares of the medical equipment provider's stock worth $594,000 after buying an additional 5,172 shares during the last quarter. Groupama Asset Managment increased its position in Hologic by 63.4% during the 4th quarter. Groupama Asset Managment now owns 54,214 shares of the medical equipment provider's stock valued at $3,918,000 after buying an additional 21,037 shares in the last quarter. Finally, Proficio Capital Partners LLC purchased a new stake in Hologic in the fourth quarter valued at about $4,215,000. 94.73% of the stock is owned by institutional investors.

Analyst Ratings Changes

HOLX has been the topic of several recent analyst reports. Royal Bank Of Canada cut their price objective on shares of Hologic from $75.00 to $70.00 and set a "sector perform" rating on the stock in a report on Friday, May 2nd. Evercore ISI decreased their price target on shares of Hologic from $65.00 to $62.00 and set an "in-line" rating for the company in a report on Friday, May 2nd. Needham & Company LLC reissued a "hold" rating on shares of Hologic in a report on Tuesday, May 27th. Raymond James Financial restated an "outperform" rating and issued a $71.00 target price (down previously from $90.00) on shares of Hologic in a research note on Friday, May 2nd. Finally, Morgan Stanley lowered their price target on Hologic from $77.00 to $65.00 and set an "equal weight" rating for the company in a research report on Monday, May 5th. Twelve research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Hologic presently has a consensus rating of "Hold" and a consensus price target of $77.42.

Hologic Stock Performance

NASDAQ HOLX traded up $0.84 during mid-day trading on Thursday, reaching $65.11. 2,404,771 shares of the stock were exchanged, compared to its average volume of 2,367,881. Hologic, Inc. has a 1 year low of $51.90 and a 1 year high of $84.67. The company has a debt-to-equity ratio of 0.54, a quick ratio of 2.52 and a current ratio of 3.24. The business's 50 day moving average is $59.70 and its 200-day moving average is $64.21. The company has a market capitalization of $14.51 billion, a P/E ratio of 27.47, a P/E/G ratio of 2.38 and a beta of 0.55.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 EPS for the quarter, beating analysts' consensus estimates of $1.02 by $0.01. The firm had revenue of $1.01 billion for the quarter, compared to analysts' expectations of $1 billion. Hologic had a return on equity of 19.71% and a net margin of 13.83%. The company's quarterly revenue was down 1.2% on a year-over-year basis. During the same period last year, the firm earned $1.03 EPS. On average, equities research analysts forecast that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Insider Transactions at Hologic

In related news, Director Martin D. Madaus purchased 5,445 shares of the business's stock in a transaction that occurred on Wednesday, May 7th. The stock was bought at an average price of $55.24 per share, with a total value of $300,781.80. Following the acquisition, the director now owns 5,445 shares in the company, valued at $300,781.80. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 1.88% of the company's stock.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.